Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19

NCT05582629 is registered in ClinicalTrials.gov with Shanghai Vinnerna Biosciences Co., Ltd. as lead sponsor.

NCT NCT05582629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19
Lead sponsor
Shanghai Vinnerna Biosciences Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 21, 2022
Completion date
February 14, 2023
Enrollment
1,369 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate covid-19